Cinical trial investigators for aducanumab (Aduhelm) discuss the significance of the drug’s recent FDA approval, the controversy surrounding its efficacy, and the uncertainty ahead….
Geri Taylor, a participant in the aducanumab (Aduhelm) clinical trial, and her husband Jim share insights about taking part in the research. UPDATE: 3…
Image: Phil Gutis receives an aducanumab infusion while carrying out his “silly shoe challenge.” Phil Gutis reflects on the significance of participating in the…
Nearly every Alzheimer’s clinical trial has been deemed a failure, yet some participants have positively responded to experimental treatment. Now, scientists are developing predictive…
Interactive gaming consoles like the Nintendo Wii and Xbox Kinect have become popular platforms, offering family-friendly exercise-related games — ‘exergames’ — such as dancing…
In 2013, Amylyx Pharmaceuticals co-founders Justin Klee and Josh Cohen, undergraduate students at Brown University at the time, hypothesized that targeting two dysfunctional pathways…
Developing a new drug start to finish can take years — even decades — and cost billions. But, there’s a shortcut: repurposing old drugs…
This weekend, Eli Lilly and Company presented detailed results of its phase 2 TRAILBLAZER-ALZ trial, showing that its investigational drug donanemab — monoclonal antibody…
The Alzheimer’s research community has been working for decades to find an effective treatment for Alzheimer’s disease, largely by targeting one of the hallmarks…
There are more than 100 experimental Alzheimer’s treatments in the pipeline, but the majority of clinical trials for potential Alzheimer’s therapies are delayed due…
This article was produced by Being Patient in partnership with Charter Research. More information on Alzheimer’s clinical trials can be found on the Charter…
Sponsored: This article was produced by Being Patient in partnership with Charter Research. More information on Alzheimer’s clinical trials can be found on the…
Benjamin Stecher was diagnosed with Parkinson’s disease at the age of 29. He has since become actively involved in Parkinson’s disease research and advocacy….
The toxic accumulation of four abnormal proteins in the brain is such a harbinger of cognitive decline, one researcher has taken to calling them…
Researchers at the Salk Institute for Biological Studies have reported that a drug candidate called CMS121 has successfully halted and possibly reversed memory loss in…